Redmile Group, LLC - 31 Dec 2024 SCHEDULE 13G/A Report for RAPT Therapeutics, Inc. Common Stock, $0.0001 par value per share (RAPT)

Filing Manager
Redmile Group, LLC
Reporting Manager
Redmile Group, LLC
Security
RAPT Therapeutics, Inc. Common Stock, $0.0001 par value per share
Symbol
RAPT
Shares outstanding
140,731,808 shares
Disclosed Ownership
13,932,449 shares
Ownership
9.9%
Form type
SCHEDULE 13G/A
Filing time
14 Feb 2025, 20:02:25 UTC
Date of event
31 Dec 2024
SEC
View on sec.gov

Quoteable Key Fact

"Redmile Group, LLC disclosed 9.9% ownership in RAPT Therapeutics, Inc. Common Stock, $0.0001 par value per share (RAPT) on 31 Dec 2024."

Quick Takeaways

  • Redmile Group, LLC filed SCHEDULE 13G/A for RAPT Therapeutics, Inc. Common Stock, $0.0001 par value per share (RAPT).
  • Disclosed ownership: 9.9%.
  • Date of event: 31 Dec 2024.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Feb 2025, 20:02.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Redmile Group, LLC 9.9% 13,932,449 0 13,932,449 /s/ Jeremy C. Green Managing Member
Jeremy C. Green 9.9% 13,932,449 0 13,932,449 /s/ Jeremy C. Green Jeremy C. Green
Redmile Biopharma Investments III, L.P. 5.4% 7,559,323 0 7,559,323 /s/ Jeremy C. Green Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P.